Previous 10 | Next 10 |
Photo by AlexanderFord/E+ via Getty Images Sorrento Therapeutics (SRNE) announced that HER2-ADC, A166 an experimental breast cancer therapy developed in partnership with Kelun-Biotech indicated a “better safety profile” and “potentially better efficacy” in a P...
A166 (ASCO Abstract #1024) is a third generation antibody drug conjugate (ADC) against HER2-positive breast cancer with Levena’s proprietary tubulin inhibitor Duo-5 toxin, cleavable linker and site-specific K-Lock™ conjugation chemistry. In this Phase 1 Study, A166 demon...
Sorrento Therapeutics ([[SRNE]] +3.9%) has entered into an additional collaborative agreement with NextGenNK Competence Center-associated research groups at the Karolinska Institutet (“KI”) in Stockholm, Sweden.The collaboration aims to produc...
SAN DIEGO and STOCKHOLM, Sweden, June 04, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the Company has entered into an additional collaborative agreement with NextGenNK Competence Center-associated research groups at t...
Palm Beach, FL – June 3, 2021 – As the world has adapted to the initial phase of the global pandemic, and vaccines are being manufactured to supply the ever growing demand, tests for the virus are in great demand themselves! COVID-19 medical tests play an important role in man...
AMONG MULTIPLE CLINICAL- AND PRECLINICAL-STAGE NCE (NEW CHEMICAL ENTITY) COMPOUNDS ACQUIRED, ABIVERTINIB IS AN ANCHORING LATE-STAGE DRUG PRODUCT WITH POSITIVE CLINICAL TRIAL RESULTS IN BOTH NON-SMALL CELL LUNG CANCER (NSCLC) AND B-CELL LYMPHOMA: Abivertinib is potentially one ...
Sorrento Therapeutics (SRNE) announces that the health regulatory authority for Mexico has listed COVI-STIX on its official government website list of rapid antigen tests approved for emergency use in the country.COVI-STIX is a rapid (~15-minute) diagnostic test for the de...
BriaCell Therapeutics (BCTX) +102% after update on the overall survival data of advanced breast cancer patients.Constellation Pharmaceuticals (CNST) +67% on merger agreement with MorphoSys.Stealth BioTherapeutics (MITO) +46% on EMA orphan drug status for elamipretide.AC Immune ...
COVI-STIX has been added to the official government list of point of care rapid antigen tests useful for the detection of SARS-CoV-2 in Mexico ( https://www.gob.mx/salud/documentos/listado-de-pruebas-de-antigeno-para-sars-cov-2 ). COVI-STIX outperformed among the tests listed ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Like the 9/11 attack or the implosion of the global financial markets in 2008, we will not soon forget the devastation of the novel coronavirus pandemic. Initially, reports about a mysterious outbreak in Wuhan, China made f...
News, Short Squeeze, Breakout and More Instantly...
Sorrento Therapeutics Inc. Company Name:
SRNE Stock Symbol:
NASDAQ Market:
Sorrento Therapeutics Inc. Website:
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...
Smart Share Global Limited (EM) is expected to report for Q1 2024 American Rebel Holdings Inc. (AREB) is expected to report for Q1 2024 First Republic Bank (San Francisco, California) (FRCB) is expected to report for Q1 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ...